

DERMATOLOGY ENROLLMENT FORM

PATIENT INFORMATION	
Last Name _____	First Name _____
Social Security # _____	Date of Birth _____
Address _____	Phone _____

TREATMENT ARRANGEMENTS
Start Date: _____
Ship Meds: <input type="checkbox"/> Home <input type="checkbox"/> Doctor's Office
Teaching by: <input type="checkbox"/> Doctor's Office
<input type="checkbox"/> Other: _____

STATEMENT OF MEDICAL NECESSITY

L40.0 Psoriasis L40.52 Psoriatic Arthritis L41.4 Plaque Psoriasis L73.2 Hidradenitis Suppurative L20.9 Atopic dermatitis L40.8 Moderate to Severe Plaque Psoriasis

Other: _____ Date of Diagnosis: _____ OR Years With Disease _____

Medication assessment (Within Last 12 Months)

Atopic dermatitis Moderate Moderate to Severe Severe

Psoriasis Severity: Moderate Moderate to Severe Severe

Psoriasis Type: Plaque Other: _____


Patient Evaluation:

- Has Patient been diagnosed with Heart Failure? Yes No
- Has Patient been diagnosed with Lymphoma? Yes No
- Does Patient have serious/active infection? Yes No
- Has TB test been performed?
If yes, results: _____ Comments: _____
- Has Hepatitis B been ruled out or treatment been initiated? Yes No
- Does Patient have latex allergy? Yes No
- Is Patient's platelet count >52,000 cells/uL? Yes No
- Patient Weight: _____ kg/lb
- Allergies: _____ NKDA

Prior (FAILED) Medications:

Medication	Reason for Discontinuation
Biologics: <input type="checkbox"/> Humira <input type="checkbox"/> Enbrel <input type="checkbox"/> Stelara	_____
<input type="checkbox"/> Others: _____	_____
<input type="checkbox"/> Methotrexate NA	_____
<input type="checkbox"/> Topicals: _____	_____

Patient Evaluation Cont.



NOTES: _____

PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILL
<input type="checkbox"/> SKYRIZI*	<input type="checkbox"/> 75mg/0.83ml Prefilled Syringe	<input type="checkbox"/> Inject 150mg (two 75mg injections) administered by Subcutaneously at week 0, weeks 4, and every 12 weeks thereafter.
<input type="checkbox"/> ILUMYA*	<input type="checkbox"/> 100mg/ml Prefilled Syringe	<input type="checkbox"/> Inject 100mg Subcutaneously at week 0, week 4 and every 12 weeks thereafter.
<input type="checkbox"/> TALTZ*	<input type="checkbox"/> 80mg/ml Autoinjector <input type="checkbox"/> 80mg/ml Prefilled Syringe	<input type="checkbox"/> Inject 160mg (two 80mg injections) Subcutaneously at week 0, followed by 80mg at Weeks 2, 4, 6, 8, 10, and 12, then 80mg every 4 Weeks.
<input type="checkbox"/> SILIQ*	<input type="checkbox"/> 210mg/1.5ml Prefilled Syringe	<input type="checkbox"/> Inject 210mg Subcutaneously at week 0, 1 and 2 followed by 210mg every 2 weeks thereafter.
<input type="checkbox"/> TREMFYA*	<input type="checkbox"/> 100mg/ml Prefilled Syringe	<input type="checkbox"/> Inject 100mg Subcutaneously at week 0, Week 4 and every 8 weeks thereafter.
<input type="checkbox"/> DUPIXENT*	<input type="checkbox"/> 300mg/2ml Prefilled Syringe	<input type="checkbox"/> Inject 600mg (2 Prefilled Syringes) Subcutaneously in different sites on day 1. <input type="checkbox"/> Inject 300mg (1 Prefilled Syringe) Subcutaneously every other week starting day 15 after initial dose.
<input type="checkbox"/> ENBREL*	<input type="checkbox"/> SureClick®Pen <input type="checkbox"/> Mini™ with Auto Touch <input type="checkbox"/> Prefilled Syringe <input type="checkbox"/> 25mg <input type="checkbox"/> 50mg <input type="checkbox"/> Vials 25mg	<input type="checkbox"/> Initial: Inject 50mg SQ twice weekly (72-96 hours apart) for 3 months. <input type="checkbox"/> Maintenance: Inject 50mg SQ weekly. <input type="checkbox"/> Others:		
<input type="checkbox"/> HUMIRA* <input type="checkbox"/> HUMIRA CF* (Citrates-free)	<input type="checkbox"/> Psoriasis STARTER Pack <input type="checkbox"/> 40mg Pen <input type="checkbox"/> 40mg Prefilled Syringe <input type="checkbox"/> Hidradenitis Suppurativa (HS) STARTER Pack <input type="checkbox"/> 40mg Pen <input type="checkbox"/> 40mg Prefilled Syringe	<input type="checkbox"/> Psoriasis STARTER Dose: Inject 80mg Subq on day 1, 40mg on day 8 and 40mg day 22 then maintenance. <input type="checkbox"/> Psoriasis Maintenance Dose: Inject 40mg Subq every other week. <input type="checkbox"/> HS Initial dose: Inject 160mg Subq on day 1, then 80mg on day 15 and then maintenance. <input type="checkbox"/> HS Maint dose: Inject 40mg Subq every week.
<input type="checkbox"/> SIMPONI*	<input type="checkbox"/> 50mg/0.5ml SmartJect Autoinjector <input type="checkbox"/> 50mg Prefilled Syringe	<input type="checkbox"/> Psoriatic Arthritis Dose: Inject 50mg (0.5ml) Subcutaneously Once a month.
<input type="checkbox"/> STELARA*	<input type="checkbox"/> 45mg/0.5ml Prefilled Syringe <input type="checkbox"/> 90mg/ml Prefilled Syringe	<input type="checkbox"/> For patients weighing < 100kg (220lbs): Inject 45mg SC initially and 4 weeks later, followed by 45mg every 12 weeks. <input type="checkbox"/> For patients weighing > 100kg (220lbs): Inject 90mg SC initially and 4 weeks later, followed by 90mg every 12 weeks.
<input type="checkbox"/> CIMZIA*	<input type="checkbox"/> 200mg/ml Prefilled Syringe	<input type="checkbox"/> Inject 400mg (given as 2 injections 200mg) Subq every other week. <input type="checkbox"/> Loading dose: Inject 400mg (given as 2 injections 200mg) Subq at week 0, 2 and 4. <input type="checkbox"/> Maintenance dose: Inject 200mg Subq every other week.
<input type="checkbox"/> OTEZLA*	<input type="checkbox"/> 10mg <input type="checkbox"/> 30mg <input type="checkbox"/> 28days starter pack	<input type="checkbox"/> Take 10mg PO qd on day 1, and increasing by 10mg daily until taking 30mg BID thereafter. <input type="checkbox"/> Take as directed by the Md.
<input type="checkbox"/> COSENTYX*	<input type="checkbox"/> Sensoready Pen <input type="checkbox"/> Prefilled-Syringe	<input type="checkbox"/> Psoriasis loading Dose: Inject 300mg (two injections) SC at weeks 0, 1, 2, 3 and 4. <input type="checkbox"/> Psoriasis Maintenance Dose: Inject 300mg (two injections) SC every 4 weeks.

Physician Signature: x _____ DAW (Dispense as Written) Date: _____

Physician Name: _____ Phone: _____ Fax: _____ Office Contact: _____

Physician Address: _____ NPI: _____ DEA: _____

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake. Then destroy this document. Please direct all verification or notification to the above mentioned physician's office.

By Signing this prescription and using Southside pharmacy's services you authorize Southside Pharmacy to contact Insurance companies for prior authorization purposes on your behalf.

FAX TO (855) - 822 - 7838

Specialty Pharmacy | IV Therapy | Home Health | Medical Equipment | Physician's Billing

7700 Main St., Houston, TX 77030 | P: 855-822-7828 | www.ssr.com

"One SOURCE for ALL your Medical NEEDS"

